‘Silver Yuan': China's geriatric healthcare a US$134 billion market by 2035, Goldman says
Wealthy Chinese consumers were likely to spend three times more than their peers on post-retirement healthcare over the next decade, the US bank said in a report published on Monday, a trend that augurs well for the growth of the so-called silver economy.
Consumers with disposable assets of at least 3 million yuan were projected to increase their annual spending on healthcare by 14.3 per cent over the next decade, Goldman said. Spending by this group of wealthy pensioners may balloon fourfold from 221 billion yuan last year.
The rise of the so-called silver yuan presents growth opportunities for geriatric healthcare services that were not currently covered in state health insurance policies, such as cataract surgeries, dental implants, vaccines against shingles and the respiratory syncytial virus, according to the report.
Medical workers provide free care to the elderly in Liupanshui, southwest China's Guizhou province, October 14, 2021. Photo: Xinhua
This group of consumers was also more likely to spend money on early screening, preventive care, and premium treatment such as specialised medications, consumables, higher-quality healthcare services, post-treatment nursing and rehabilitation, the report said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
17 hours ago
- South China Morning Post
China trio diagnosed with bacterial infection after eating ‘nutritious' cooked sheep placenta
Three people in China had to be hospitalised after they ate sheep placenta for 'nutritious' purposes, sparking an online discussion about the custom. A woman, surnamed Zhang, in southern China's Guangdong province was reported to have developed frequent fevers and lost 5kg in weight over a short period after she cooked the 'dish'. She went to hospital and was diagnosed with brucellosis, a type of bacterial infection spread from animals to humans. One of the victims suffered serious weight loss and fevers after eating the sheep placenta 'dish'. Photo: Shutterstock Zhang's sister and brother-in-law were diagnosed with the same disease after eating the 'tonic'. The placenta is an organ that forms in the uterus during pregnancy and is considered a highly nutritious ingredient in China. In Traditional Chinese Medicine, the placenta is known as ziheche. It is believed to strengthen the immune system, treat fatigue, infertility and a lack of energy.
South China Morning Post
18 hours ago
- South China Morning Post
Hong Kong reports first chikungunya case in four years: learn how to protect yourself
Hong Kong has confirmed its first imported case of chikungunya fever since 2019. The case involves a 12-year-old boy and has prompted health authorities to urge residents to be more vigilant against this mosquito-borne disease. Should residents be concerned about a potential local outbreak? What preventive measures should be taken? The South China Morning Post provides a detailed breakdown of the situation for you. 1. What happened to the boy? The head of the communicable disease branch of the Centre for Health Protection, Dr Albert Au Ka-wing, said the boy lived in Kwun Tong's On Tat Estate and was diagnosed with the disease after returning from mainland China. He travelled with his mother to Foshan's Shunde district, where an outbreak is ongoing, from July 17 to 30 and reported being bitten by mosquitoes while outside. He developed a fever, rash and joint pain on Thursday and was confirmed to be infected on Saturday morning after being admitted to United Christian Hospital. The government said on Sunday that the boy had been transferred to Princess Margaret Hospital in Kwai Chung and remained in a stable condition. His household contacts were currently asymptomatic and under medical surveillance. The Housing Authority and the Food and Environmental Hygiene Department stepped up anti-mosquito efforts at Kwun Tong's On Tat Estate and United Christian Hospital over the weekend. The measures include setting up more traps, applying larvicidal oil in breeding spots, clearing stagnant water and grass near drainage holes, strengthening disinfection and conducting outreach efforts to remind residents to clean water from flower pots. 2. What are the symptoms? Is it fatal? Chikungunya fever's symptoms are similar to those of dengue fever and include fever, rashes and joint pain, particularly in the hands and feet. A key difference is that chikungunya fever is generally milder than dengue, which can lead to more severe conditions like haemorrhagic fever. The medical director of the Hospital Authority's infectious disease centre, Jacky Chan Man-chun, said severe complications and death from chikungunya were 'extremely rare'. According to the World Health Organization, they usually occur in young babies or elderly people with other coexisting health problems. The disease is transmitted through bites from the Asian tiger mosquito. Photo: zb/dpa 3. Which mosquitoes spread the virus? The virus is spread through the bites of infected mosquitoes and is not transmitted from person to person through daily social contact. Two types of mosquito can transmit the virus: the Aedes aegypti, or yellow fever mosquito; and the Aedes albopictus. The Aedes albopictus, or the Asian tiger mosquito, is a very common species found in Hong Kong. 4. What preventive measures should I take if travelling? Officials stressed that the disease is preventable by avoiding mosquito bites. Travellers are advised to take full personal protective measures, including using mosquito repellent. To protect yourself from mosquito bites when travelling, you should wear loose-fitting, light-coloured, long-sleeved tops and long trousers. It is also essential to apply an insect repellent containing DEET to any exposed skin and onto your clothing. For pregnant women and children aged six months or older, DEET products are usable, but it is recommended to adhere to a concentration limit of 30 per cent for pregnant women and 10 per cent for children. For additional outdoor protection, avoid using cosmetics or skincare products with a fragrance. Remember to reapply insect repellent as directed by the product instructions. Apply sunscreen before repellent if using both. Taking general measures to prevent mosquitoes from breeding in your vicinity is also a key part of staying protected. 5. What should I do if I display symptoms? Anyone who develops symptoms after returning from an affected area should seek medical advice promptly and, crucially, tell their doctor their travel history. The government provides free testing for suspected cases, which requires a blood sample sent to a laboratory. Officials also strongly advise that anyone returning from affected areas should continue to use mosquito repellent for 14 days upon arrival to prevent any potential transmission to local mosquitoes, even if they do not have symptoms. The head of the Food and Environmental Hygiene Department's rodent risk assessment and advisory unit, Anita Fok (from left), the head of the communicable disease branch of the Centre for Health Protection, Albert Au, and the medical director of the Hospital Authority's infectious disease centre, Jacky Chan. Photo: Edmond So 6. How long will a patient take to recover? Most patients recover on their own without specific antiviral medication. The 12-year-old patient's fever and joint pain had already disappeared by Saturday morning, with only a mild rash remaining. However, in some high-risk individuals such as the elderly, joint pain can persist as a long-term symptom. According to expert Yuen Kwok-yung of the University of Hong Kong, the joint inflammation and swelling can persist for more than three months in about 40 per cent of patients. 7. Are there any vaccines available? Two new vaccines exist globally, but both are very new and not yet widely used, Au said. The World Health Organization is still reviewing their safety and efficacy data, and they are not currently registered for use in Hong Kong. 8. Any chance of an outbreak in Hong Kong? The risk of small-scale local transmission is a possibility, especially as mild cases may go undiagnosed. A mosquito can spread the virus as quickly as two days after biting an infected person, much faster than the eight days required for dengue, which allows for rapid transmission where populations have no immunity. The risk of further imported cases was considered high due to frequent summer travel between Hong Kong and Guangdong, Au said, adding that the government had been preparing for several weeks. 'We do not rule out that with some imported cases, there may be some local transmission in Hong Kong,' Au said. 'The risk is medium to high.' However, officials said the risk of a widespread outbreak or the disease becoming endemic was 'extremely low', thanks to a robust surveillance system and improved local mosquito control this year compared with the past two years. The head of the Food and Environmental Hygiene Department's rodent risk assessment and advisory unit, Anita Fok Ming-yan, said teams had already begun intensive mosquito control work around the patient's home and hospital. 'We again appeal to the public to strengthen anti-mosquito work in their own premises,' she said.
South China Morning Post
21 hours ago
- South China Morning Post
Innovent, BeOne are poised for profits in 2025, in milestone for Chinese biotech start-ups
Innovent likely to post a first-half net profit of US$36.4 illion, and BeOne's first-half net rofit is expected to come in at US$42 million A pair of Hong Kong-listed mainland Chinese biotechnology firms are poised to turn a profit this year as their revenue from novel drugs finally outstrips costs related to research and development and marketing, according to analysts. 'Chinese biotechs have matured significantly and are creating value for Chinese patients and government payers,' said Tony Ren, head of Asia healthcare research at Macquarie Capital, in a report on July 16. '[Some will] likely turn profitable soon and no longer rely on investors for funding.' Suzhou-based Innovent Biologics, the first Chinese company to be approved to sell a drug for weight loss and diabetes, is expected to swing to a first-half net profit of 260 million yuan (US$36.4 million) from a year-earlier loss of 392.6 million yuan, according to an estimate from Zhang Jialin, Nomura's head of China healthcare research. According to a consensus estimate from Bloomberg, the company was expected to post a net profit of 472 million yuan for 2025, its first full-year profit since going public. Innovent, founded in 2011, was one of the first batch of firms to go public in 2018 under a Hong Kong listing regime that allowed drug and medical device developers with no profit or revenue to sell shares. Innovent Biologics is expected to post a first-half net profit of 260 million yuan compared with a loss of 392.6 million yuan a year earlier. Photo: Handout In the second half, Zhang estimated that Innovent would book 1 billion yuan in sales from mazdutide, a glucagon-like peptide-1 (GLP-1) weight loss drug launched in July. That would amount to a sixth of the company's total expected revenue for this year, making it a key contributor to the improved bottom line. Novo Nordisk's semaglutide, the first GLP-1 drug launched in China last year for weight loss, generated revenue of 770 million yuan in the first quarter. A researcher using a micropipette pipette in a lab. Photo: Shutterstock BeOne, a developer of oncology drugs that was established in 2010, was expected by analysts to post a net profit of US$42 million for the first half and a full-year profit of US$109.5 million. The company will announce its first-half results on August 6. Newsletter Every Saturday SCMP Global Impact By submitting, you consent to receiving marketing emails from SCMP. If you don't want these, tick here {{message}} Thanks for signing up for our newsletter! Please check your email to confirm your subscription. Follow us on Facebook to get our latest news. The company's profit growth was driven primarily by sales of its blood cancer drug zanubrutinib in the US and Europe, Zhang said. Innovent and BeOne, along with other Chinese biotech firms like Akeso, have booked billions of yuan in upfront revenue over the past few years from licensing drug candidates to multinational partners for overseas development. But despite an increase in deals in recent years, milestone payments in the drug development process were hard to predict because collaborations were often cut short due to shifting competitive considerations and regulatory hurdles, Macquarie's Ren said. For example, the US Food and Drug Administration (FDA) in March 2022 rejected an application from Eli Lilly to sell Innovent's lead oncology drug, sintilimab, to treat the most common type of lung cancer in the US, even though it was approved in China a year earlier. While the FDA recommended that an additional multi-regional clinical study be conducted, the drug has still not been approved in the US. In mid-2019, Celgene returned to BeOne the exclusive right to develop and commercialise the Chinese firm's immunotherapy drug candidate, tislelizumab, ahead of Celgene's impending acquisition by Bristol-Myers Squibb. The American drug firm already had an approved treatment in the same category. Celgene terminated the deal by paying BeOne US$150 million. In 2021, BeOne re-licensed the rights for the same drug to Switzerland's Novartis, which in 2023 returned them, citing a changing market landscape. BeOne subsequently took over the drug's development and won approvals to launch it in the European Union and the US. 'Most licensing deals, including ones from China, are small [in actual payments] and hardly affect the licensers' financial performance over the medium to long term,' Ren said.
